← Eichor
Study identifier: NCT03263130 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Site and Mechanism(s) of Expiratory Airflow Limitation in COPD, Emphysema and Asthma-COPD Overlap

Condition: COPD, Emphysema, Asthma COPD Overlap · Emphysema  ·  Sponsor: Gelb, Arthur F., M.D.

PhaseN/A
Planned participants60
Who can joinAll sexes, 30 Years to no upper limit
Healthy volunteersYes

About this study

The purpose of this cross-sectional, observational study is to evaluate the site and mechanism(s) for expiratory airflow limitation in chronic, treated, current or former smokers (\>15 pack years) with COPD, Emphysema, and Asthma-COPD Overlap with mild to severe expiratory airflow limitation. Treatment may include short and long acting inhaled beta2agonists, short and long acting inhaled muscarinic receptor antagonists, inhaled and or oral corticosteroid, oral antibiotic, supplemental oxygen, and PDE type 4 inhibitor. In some cases, the patient may have had a history of asthma preceding the development of COPD (Asthma COPD Overlap).

This description comes directly from the study's public registry record.

Talk to the study team

Arthur F Gelb, MD  ·  562-633-2204  ·  afgelb@msn.com

Christine Fraser  ·  562-633-2204  ·  familyfrase@msn.com

Always discuss trial participation with your own doctor first.

Locations (2)

Arthur F Gelb MDLakewood, California, United StatesRecruiting
Arthur F Gelb MDLakewood, California, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT03263130